
==== Front
JAAD Int
JAAD Int
JAAD International
2666-3287
Elsevier

S2666-3287(24)00108-1
10.1016/j.jdin.2024.07.010
Research Letter
Vitiligo may be associated with an increased genetic risk of cardiovascular disease: A Mendelian randomization study
Piontkowski Austin J. BS
Dubin Celina MD
O’Hagan Ross MD
Orloff Jeremy BA
Powers Camille M. BS
Gulati Nicholas MD, PhD nicholas.gulati@mssm.edu
∗
Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
∗ Correspondence to: Nicholas Gulati, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th St, 5th Floor, New York, NY 10029 nicholas.gulati@mssm.edu
12 8 2024
12 2024
12 8 2024
17 2123
© 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.
2024
American Academy of Dermatology, Inc.
https://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Key words

cardiovascular disease
clinical research
general dermatology
medical dermatology
Mendelian randomization
vitiligo
==== Body
pmcTo the Editor: Vitiligo is an inflammatory disease that causes patchy depigmentation of the skin. Recent findings suggest a link between vitiligo and cardiovascular disease (CVD), although the existence of a genetic and causal relationship remains unknown. This study seeks to explore the relationship between vitiligo and CVD through the application of Mendelian randomization (MR). Utilizing data from genome-wide association studies (GWAS), MR leverages genetic variation to estimate the causal effects of an exposure on an outcome.1 The strategic use of genetic variants effectively eliminates confounding bias, enabling a robust analysis of the causal effects that vitiligo may have on CVD.

GWAS summary statistics were obtained for vitiligo from the GWAS Catalog, a collaborative effort by the National Human Genome Research Institute and European Bioinformatics Institute. This dataset included 8,966,111 single-nucleotide polymorphisms (SNPs) derived from 4680 vitiligo patients and 39,586 controls. Summary statistics for CVD were obtained from the Integrative Epidemiology Unit Open GWAS Project, including 16,380,466 SNPs among 101,866 cases and 116,926 controls. An MR analysis was then performed using the inverse-variance weighted and weighted median methods. Genes associated with SNPs exhibiting an odds ratio (OR) >1.00 were subsequently included in an enrichment analysis. All analyses took place within R version 4.3.1 using the packages “TwoSampleMR” and “enrichR” (Supplementary Methods, available via Mendeley at https://doi.org/10.17632/984w22jmcy.1).

Overall, MR revealed a significant association between vitiligo and CVD with both the inverse-variance weighted method (OR = 1.03, β = 0.029, P = .014) and the weighted median method (OR = 1.02, β = 0.021, P = .047). There was no evidence to suggest the presence of horizontal pleiotropy (MR Egger P = .323). Five significant SNPs (OR >1) were identified, namely: (1) rs10774624, a single nucleotide variation (SNV) of LINC02356; (2) rs2476601, a SNV of PTPN22, linked to autoimmune conditions; (3) rs12421615, a SNV of PLCB3, encoding phospholipase C beta-3; (4) rs1043101, a SNV of SLC1A2, involved in glutamate clearance; and (5) rs2111485, a SNV of IFIH1, involved in innate immunity (Fig 1). Enrichment analysis further revealed several key pathways involved in the regulation of proinflammatory cytokines, B-cell receptor signaling, and natural killer cells (Fig 2).Fig 1 Forest plot depicting the odds of cardiovascular disease for individual single-nucleotide polymorphisms (SNPs) (left axis) and corresponding genes (right axis).

Fig 2 Enrichment analysis of genes corresponding to single-nucleotide polymorphisms (SNPs) with an odds ratio greater than 1.00 utilizing the Gene Ontology Cellular Component 2023 library within the Enrichr database.

This study demonstrates, to our knowledge, the first causal relationship between vitiligo and CVD. Recent research has demonstrated increased rates of hypercholesterolemia and atherosclerosis in vitiligo patients, postulating that the proinflammatory mediators implicated in vitiligo, such as tumor necrosis factor-alpha, interleukin-1, and interleukin-6, also contribute to the development of CVD.2, 3, 4 Our findings align with this hypothesis, as the SNPs and enriched pathways driving this relationship are primarily involved in cell signaling, immunity, and inflammation. However, the use of MR in parameter estimation is often constrained in clinical settings.5 Furthermore, the modest magnitude of causal estimates observed in this study may be indicative of compounded estimates that are not representative of the primary SNPs influencing this relationship and the existence of other explanatory variables. Nonetheless, these results unveil a clear genetic predisposition to CVD among vitiligo patients. Consequently, there is a need for heightened surveillance and additional research into preventative care strategies for these patients, as well as risk stratification by racial and ethnic backgrounds.

Conflicts of interest

None disclosed.

We would like to acknowledge the National Human Genome Research Institute, European Bioinformatics Institute, Integrative Epidemiology Unit Open GWAS Project, and FinnGen research project, whose work has made this study possible.

Funding sources: None.

Patient consent: Not applicable.

IRB approval status: Not applicable/exempt.

Data sharing statement: All data that support these findings are publicly available via the IEU OpenGWAS Project and the NHGRI-EBI GWAS Catalog.
==== Refs
References

1 Sanderson E. Glymour M.M. Holmes V.M. Mendelian randomization Nat Rev Methods Primers 2 1 2022 6 37325194
2 Azzazi Y. Mostafa Z.W. Sayed S.K. Support for increased cardiovascular risk in non-segmental vitiligo among Egyptians: a hospital-based, case–control study Pigment Cell Melanoma Res 34 3 2021 598 604 33098225
3 Gholijani N. Yazdani M.R. Dastgheib L. Predominant role of innate pro-inflammatory cytokines in vitiligo disease Arch Dermatol Res 312 2 2020 123 131 31620869
4 Namazi N. Amani M. Haghighatkhah R.H. Noori E. Abdollahimajd F. Increased risk of subclinical atherosclerosis and metabolic syndrome in patients with vitiligo: a real association or a coincidence? Dermatol Ther 34 2 2021 e14803
5 Burgess S. Labrecque J.A. Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates Eur J Epidemiol 33 2018 947 952 10.1007/s10654-018-0424-6 30039250
